COPD exacerbations:: the importance of a standard definition

被引:92
作者
Pauwels, R
Calverley, P
Buist, AS
Rennard, S
Fukuchi, Y
Stahl, E
Löfdahl, CG
机构
[1] Ghent Univ Hosp, Dept Resp Dis, B-9000 Ghent, Belgium
[2] Aintree Univ Hosp NHS Fdn Trust, Dept Med, Liverpool, Merseyside, England
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Univ Nebraska, Med Ctr, Omaha, NE USA
[5] Juntendo Univ, Dept Internal Med, Div Resp Med, Tokyo, Japan
[6] Univ Lund Hosp, Dept Resp Med & Allergol, S-22185 Lund, Sweden
[7] AstraZeneca R&D, Lund, Sweden
关键词
COPD; exacerbation; definition;
D O I
10.1016/j.rmed.2003.09.001
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Efforts to assess the efficacy of new therapies in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD) have been hampered by the lack of a widely agreed and consistently used definition. A variety of definitions have been used in clinical studies, based on changes in patient symptoms or the requirement for antibiotic therapy, oral steroids or hospitalisation. To date, none of these definitions have been assessed in detail for their reliability, responsiveness and validity determined. Considerable heterogeneity in the aetiology and manifestation of COPD exacerbations makes identification and quantification of defining symptoms extremely difficult. New approaches are therefore being sought with a view to identifying a serum or tissue marker that can be used as a valuable diagnostic tool Improvements in data recording will also contribute to the accuracy of data retrieval and assessment. if we are to progress to a level of sophistication seen in the diagnosis and management of other diseases, it is evident that considerable research efforts will be required to improve our understanding of COPD exacerbations and develop a standard definition for these events, thereby facilitating the assessment of therapeutic approaches. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:99 / 107
页数:9
相关论文
共 52 条
[1]
ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
ANTHONISEN, NR ;
MANFREDA, J ;
WARREN, CPW ;
HERSHFIELD, ES ;
HARDING, GKM ;
NELSON, NA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) :196-204
[2]
Balbi B, 1997, EUR RESPIR J, V10, P846
[3]
Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations [J].
Bhowmik, A ;
Seemungal, TAR ;
Sapsford, RJ ;
Wedzicha, JA .
THORAX, 2000, 55 (02) :114-120
[4]
Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease [J].
Bhowmik, A ;
Seemungal, TAR ;
Sapsford, RJ ;
Devalia, JL ;
Wedzicha, JA .
THORAX, 1998, 53 (11) :953-956
[5]
BLASI F, 1993, EUR RESPIR J, V6, P19
[6]
RANDOMIZED CONTROLLED TRIAL OF NASAL VENTILATION IN ACUTE VENTILATORY FAILURE DUE TO CHRONIC OBSTRUCTIVE AIRWAYS DISEASE [J].
BOTT, J ;
CARROLL, MP ;
CONWAY, JH ;
KEILTY, SEJ ;
WARD, EM ;
BROWN, AM ;
PAUL, EA ;
ELLIOTT, MW ;
GODFREY, RC ;
WEDZICHA, JA ;
MOXHAM, J .
LANCET, 1993, 341 (8860) :1555-1557
[7]
NONINVASIVE VENTILATION FOR ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
BROCHARD, L ;
MANCEBO, J ;
WYSOCKI, M ;
LOFASO, F ;
CONTI, G ;
RAUSS, A ;
SIMONNEAU, G ;
BENITO, S ;
GASPARETTO, A ;
LEMAIRE, F ;
ISABEY, D ;
HARF, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (13) :817-822
[8]
*BTS GUID MAN CHRO, 1997, THORAX S, V5, pS1
[9]
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[10]
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].
Calverley, P ;
Pauwels, R ;
Vestbo, J ;
Jones, P ;
Pride, N ;
Gulsvik, A ;
Anderson, J ;
Maden, C .
LANCET, 2003, 361 (9356) :449-456